远程缺血适应治疗急性卒中:RESIST随机临床试验
这项在丹麦4个卒中中心开展的随机临床试验纳入1500例院前卒中症状持续不足4小时的患者,比较远程缺血适应(RIC)与假治疗对90天功能结局的影响。在902例最终诊断为卒中的患者中,RIC组90天改良Rankin量表(mRS)评分中位数为2,假治疗组为1,RIC未显著改善功能结局(OR 0.95,95%CI 0.75-1.20,P=0.67)。
要点
- 院前启动并院内继续的RIC未显著改善急性卒中患者90天功能结局(OR 0.95,95%CI 0.75-1.20,P=0.67)。
- RIC组与假治疗组严重不良事件数量无显著差异(23.7% vs 24.3%,OR 0.97,95%CI 0.85-1.11,P=0.68)。
- 治疗期间上肢疼痛和/或皮肤瘀点见于RIC组54例(7.2%)与假治疗组11例(1.5%)。
核心结论
- 院前启动并院内继续的远程缺血适应未显著改善急性卒中患者90天功能结局。
研究设计与样本
- 在丹麦4个卒中中心开展的随机临床试验,纳入1500例院前卒中症状持续不足4小时的患者,入组时间为2018年3月16日至2022年11月11日,末次随访为2023年2月3日。
主要发现
- 在902例最终诊断为卒中的患者中(737例[82%]为缺血性卒中,165例[18%]为脑出血),436例接受RIC,466例接受假治疗。
- 90天mRS评分中位数在RIC组为2(IQR 1-3),在假治疗组为1(IQR 1-3);RIC与90天功能结局改善无显著关联(OR 0.95,95%CI 0.75-1.20,P=0.67;mRS评分中位数绝对差异为-1,95%CI -1.7至-0.25)。
- 在所有随机化患者中,严重不良事件数量无显著差异:RIC组169例(23.7%)发生1次或以上严重不良事件,假治疗组175例(24.3%)(OR 0.97,95%CI 0.85-1.11,P=0.68)。
- 治疗期间上肢疼痛和/或皮肤瘀点见于RIC组54例(7.2%)与假治疗组11例(1.5%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Despite some promising preclinical and clinical data, it remains uncertain whether remote ischemic conditioning (RIC) with transient cycles of limb ischemia and reperfusion is an effective treatment for acute stroke. OBJECTIVE: To evaluate the effect of RIC when initiated in the prehospital setting and continued in the hospital on functional outcome in patients with acute stroke. DESIGN, SETTING, AND PARTICIPANTS: This was a randomized clinical trial conducted at 4 stroke centers in Denmark that included 1500 patients with prehospital stroke symptoms for less than 4 hours (enrolled March 16, 2018, to November 11, 2022; final follow-up, February 3, 2023). INTERVENTION: The intervention was delivered using an inflatable cuff on 1 upper extremity (RIC cuff pressure, ≤200 mm Hg [n = 749] and sham cuff pressure, 20 mm Hg [n = 751]). Each treatment application consisted of 5 cycles of 5 minutes of cuff inflation followed by 5 minutes of cuff deflation. Treatment was started in the ambulance and repeated at least once in the hospital and then twice daily for 7 days among a subset of participants. MAIN OUTCOMES AND MEASURES: The primary end point was improvement in functional outcome measured as a shift across the modified Rankin Scale (mRS) score (range, 0 [no symptoms] to 6 [death]) at 90 days in the target population with a final diagnosis of ischemic or hemorrhagic stroke. RESULTS: Among 1500 patients who were randomized (median age, 71 years; 591 women [41%]), 1433 (96%) completed the trial. Of these, 149 patients (10%) were diagnosed with transient ischemic attack and 382 (27%) with a stroke mimic. In the remaining 902 patients with a target diagnosis of stroke (737 [82%] with ischemic stroke and 165 [18%] with intracerebral hemorrhage), 436 underwent RIC and 466 sham treatment. The median mRS score at 90 days was 2 (IQR, 1-3) in the RIC group and 1 (IQR, 1-3) in the sham group. RIC treatment was not significantly associated with improved functional outcome at 90 days (odds ratio [OR], 0.95; 95% CI, 0.75 to 1.20, P = .67; absolute difference in median mRS score, -1; -1.7 to -0.25). In all randomized patients, there were no significant differences in the number of serious adverse events: 169 patients (23.7%) in the RIC group with 1 or more serious adverse events vs 175 patients (24.3%) in the sham group (OR, 0.97; 95% CI, 0.85 to 1.11; P = .68). Upper extremity pain during treatment and/or skin petechia occurred in 54 (7.2%) in the RIC group and 11 (1.5%) in the sham group. CONCLUSIONS AND RELEVANCE: RIC initiated in the prehospital setting and continued in the hospital did not significantly improve functional outcome at 90 days in patients with acute stroke. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03481777.
引用
- Blauenfeldt RA, Hjort N, Valentin JB, et al. Remote Ischemic Conditioning for Acute Stroke: The RESIST Randomized Clinical Trial. JAMA. 2023. PMID: 37787796. doi:10.1001/jama.2023.16893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。